Latest Genetic disorders Stories

BEIJING, June 25, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang") has received a manufacturing approval certificate from the China State Food and Drug Administration ("SFDA") for Human Coagulation Factor VIII ("FVIII"). With this...

Meeting to Take Place at Annual Connect Conference in Ft. Lauderdale HACKENSACK, N.J., June 25, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) will host the first Transforming Duchenne Care Meeting, June 27-28, 2012, immediately preceding the Annual Connect Conference in Fort Lauderdale, Florida. The goal of the Transforming Duchenne Care Meeting is to bring together leadership from top medical institutions, neuromuscular experts, and patient...

HORSHAM, Pa., June 25, 2012 /PRNewswire/ -- In advance of releasing his debut album, musician and American Idol alumnus Casey Abrams has created an original song entitled "Chip on Your Shoulder" and music video inspired by his personal experience with inflammatory bowel disease (IBD) and the people he met through the national disease awareness campaign IBD Icons. Starting today, people can view Abrams' music video by joining the fan club at www.IBDIcons.com. For every fan who...

Expectant parents to get latest, culturally-appropriate information on Down syndrome BOSTON, June 23, 2012 /PRNewswire-USNewswire/ -- Friday was a historic day for people with Down syndrome, their families and those who love them. Just after noon, in the Massachusetts Governor's chambers, surrounded by legislative leaders, parents of people with Down syndrome and self-advocates, Governor Deval Patrick signed landmark legislation that promises a bright future for the Down syndrome...

'A Molecular Bandage for Diseased Muscle' appears today in prestigious Science publication Leading muscular dystrophy researcher Dean Burkin, of the University of Nevada School of Medicine summarizes the impact of a new protein therapeutic, MG53, for the treatment of Duchenne muscular dystrophy in an article published this week in Science Translational Medicine. "This is a focus article in which we summarize the impact of MG53 protein therapy as a treatment option and discuss the...

Strategic focus and robust portfolio of services continue to create record distribution trend for specialty biotech distributor BDI Pharma. Columbia, SC (PRWEB) June 21, 2012 BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, after finishing the previous calendar year with a record level of distribution in anti-hemophilic factor (AHF), announced today that through the first five (5) months of 2012, the company’s distribution is tracking...

(Ivanhoe Newswire) – More than 15,000 Americans have Huntington’s disease, a fatal condition marked by uncontrolled movements and cognitive and psychiatric problems. Currently, there are no available treatments to alter the effects of Huntington’s disease, but a new study brings researchers one step closer to finding one. A new gene-silencing strategy can reverse core symptoms associated with Huntington's disease, according to a preclinical study. The short-term therapy produced...

Single treatment produces long-term improvement in animal models With a single drug treatment, researchers at the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine can silence the mutated gene responsible for Huntington's disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models. Researchers suggest the drug therapy, tested in mouse and non-human primate models, could produce sustained...

A new gene-silencing strategy can reverse core symptoms associated with Huntington's disease, according to a preclinical study published by Cell Press in the June 21st issue of the journal Neuron. The short-term therapy produced sustained benefits in both mouse and primate animal models of this neurodegenerative disorder, which currently lacks an effective treatment. "Our approach is feasible for development now into a therapy for Huntington's disease in man," says senior study author Don...

Legislation Includes Measures to Increase Patient and Expert Participation in FDA Review of Rare Disease Medicines BETHESDA, Md., June 20, 2012 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation issued the following statement in response to passage of legislation today in the House of Representatives to expand consultation between the Food and Drug Administration (FDA) and external rare disease experts and patient advocates during the FDA drug approval process. The bill is...